3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
4
Status
Recruiting
3
Active not recruiting
1
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Gynecologic
4
Conditions
Carcinoma, Non-Small-Cell Lung
51
Prostatic Neoplasms
23
Lung Neoplasms
17
Breast Neoplasms
15
Squamous Cell Carcinoma of Head and Neck
13
Stomach Neoplasms
10
Parkinson Disease 4, Autosomal Dominant Lewy Body
8
Neoplasms
8
Urinary Bladder Neoplasms
6
Carcinoma, Transitional Cell
6
Triple Negative Breast Neoplasms
5
Non-Muscle Invasive Bladder Neoplasms
5
Neoplasm Metastasis
5
Head and Neck Neoplasms
5
Carcinoma, Squamous Cell
5
Prostatic Neoplasms, Castration-Resistant
4
Ovarian Neoplasms
4
Oropharyngeal Neoplasms
4
Endometrial Neoplasms
4
Small Cell Lung Carcinoma
3
Salivary Gland Neoplasms
3
Nasopharyngeal Carcinoma
3
Laryngeal Neoplasms
3
HER2-positive Breast Cancer
3
Fallopian Tube Neoplasms
3
Anatomic Stage I Breast Cancer AJCC v8
3
Adenocarcinoma
3
Solid Tumors
2
Sarcoma
2
Osteosarcoma
2
Interventions
pembrolizumab
23
Paclitaxel
23
Carboplatin
15
Specimen Handling
13
Bevacizumab
12
Magnetic Resonance Spectroscopy
10
Doxorubicin
8
Biopsy
8
lenvatinib
7
Taxes
7
olaparib
6
Letrozole
6
Fulvestrant
6
Cisplatin
6
dostarlimab
5
Nivolumab
5
Gemcitabine
5
abemaciclib
4
X-Rays
4
Trastuzumab
4
Oxaliplatin
4
Medroxyprogesterone Acetate
4
Immunoglobulin G
4
Fluorouracil
4
Docetaxel
4
trastuzumab deruxtecan
3
palbociclib
3
ipatasertib
3
durvalumab
3
Tirzepatide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
Docetaxel
×
90 days
×
Clear all
NCT06952504
2026-05-22
TroFuse-033
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,123 enrolled
NCT06340568
2026-05-20
Fern-EC-01
BioNTech SE
Phase 3
Recruiting
480 enrolled
NCT06989112
2026-05-06
DE-01
AstraZeneca
Phase 3
Recruiting
600 enrolled
NCT05173987
2026-05-05
KEYNOTE-C93
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
280 enrolled